Statement Pursuant to Listing Rule 4.7C.3

Statement Pursuant to Listing Rule 4.7C.3

Imagion Biosystems advises that in accordance with Listing Rule 4.7C.3, and as noted in the Item 6 of the Appendix 4C Cashflow Statement lodged by the Company with the Australian Securities Exchange (ASX) on 27 October 2020, payments to related parties and their associates during the quarter ended 30 September 2020 were $115k. These payments related to Directors fees and executive salaries.

Read the statement.

Related Articles

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.